IMMUNITYBIO, INC. Payments to Acquire Held-to-maturity Securities
IMMUNITYBIO, INC. (IBRX) reported Payments to Acquire Held-to-maturity Securities of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2021-03-04
- IMMUNITYBIO, INC. payments to acquire held-to-maturity securities for the quarter ending 2019-12-31 was $0.00.
- IMMUNITYBIO, INC. payments to acquire held-to-maturity securities for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. payments to acquire held-to-maturity securities for the quarter ending 2018-12-31 was $0.00.
- IMMUNITYBIO, INC. payments to acquire held-to-maturity securities for the quarter ending 2018-09-30 was $362.00K.
- IMMUNITYBIO, INC. payments to acquire held-to-maturity securities for fiscal 2020 was $0.00.
- IMMUNITYBIO, INC. payments to acquire held-to-maturity securities for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- IMMUNITYBIO, INC. payments to acquire held-to-maturity securities for fiscal 2018 was $723.00K.
- IMMUNITYBIO, INC. payments to acquire held-to-maturity securities for fiscal 2017 was $0.00.
| Period end | Payments to Acquire Held-to-maturity Securities 3 month | Payments to Acquire Held-to-maturity Securities 6 month | Payments to Acquire Held-to-maturity Securities 9 month | Payments to Acquire Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-04 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $0.00 derived: sum of 2 quarters · filed 2021-03-04 | $0.00 10-K · filed 2021-03-04 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | ||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-06 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $362.00K derived: sum of 2 quarters · filed 2021-03-04 | $723.00K 10-K · filed 2021-03-04 | |
| 2018-09-30 | $362.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $723.00K 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $361.00K 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $0.00 derived: sum of 2 quarters · filed 2020-03-25 | $0.00 10-K · filed 2020-03-25 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-06 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |